부피바카인염산염 주사제 시장 예측(-2030년) : 농도, 용량, 포장, 용도, 최종사용자, 지역별 세계 분석

According to Stratistics MRC, the Global Bupivacaine Hydrochloride Injection Market is accounted for $1120.21 million in 2023 and is expected to reach $1870.27 million by 2030 growing at a CAGR of 7.6% during the forecast period. Bupivacaine Hydrochloride Injection is a medication used in the field of anaesthesia and pain management. It is a local anaesthetic that is administered via injection to numb specific areas of the body. Bupivacaine works by blocking the transmission of pain signals along nerve fibers. Bupivacaine should be administered with caution, especially in high-risk patients or in situations where close monitoring is required. Bupivacaine should not be used in patients with known allergies to the drug.

According to the American Academy of Orthopedic Surgeons (AAOS) survey, over 432,000 spinal fusions are performed in the United States every year. As per the Agency for Healthcare Research and Quality, more than 790,000 knee replacements are performed yearly in the United States.

Market Dynamics:

Driver:

Rising demand for ambulatory surgical centers

ASCs are increasingly performing a wide range of surgical procedures, including orthopedic, ophthalmic, gynaecological, and dental surgeries. These centers often prefer using local anaesthetics like Bupivacaine Hydrochloride Injection for their ability to provide effective anaesthesia while allowing patients to recover quickly and go home on the same day. Also, ASCs are known for their cost-effective approach to healthcare delivery. As well as, its minimization of opioid usage, reduced risk of side effects and quick turnaround times are fuelling the market growth.

Restraint:

Stringent regulatory approval process

Regulatory authorities, such as the FDA in the United States, set high safety and efficacy standards for medications. Even after significant investment in the regulatory approval process, there is a risk of rejection or delays in approval. Even after approval, companies must comply with ongoing post-market surveillance and reporting requirements. Therefore, regulatory approval status can influence pricing and reimbursement decisions. Meeting these standards is essential but can be challenging for the market.

Opportunity:

Growing surgical procedures

Surgical procedures, whether major or minor, typically require anaesthesia to ensure patient comfort and safety during the operation. Bupivacaine Hydrochloride is a widely used local anaesthetic that provides effective pain relief during and after surgery. Bupivacaine Hydrochloride is commonly used in regional anaesthesia techniques. The rise in minimally invasive surgical procedures often involves regional anaesthesia techniques. Its applications in wide range of surgical specialties and minimally invasive procedures are propelling the market growth.

Threat:

Competition from generic versions

Generic versions of bupivacaine hydrochloride injections typically enter the market at lower prices than their branded counterparts. This can lead to price competition and erosion of profit margins for the original manufacturer. This may prompt mergers, acquisitions, or partnerships among manufacturers to achieve economies of scale and maintain profitability. It can also lead to market saturation. All these elements hinder the market demand.

COVID-19 Impact

The COVID-19 pandemic had several impacts on the pharmaceutical industry. The pandemic led to disruptions in global supply chains due to lockdowns, restrictions on transportation, and workforce shortages. This affected the availability and distribution of Bupivacaine Hydrochloride Injection. Many elective surgeries were postponed or cancelled during the peak of the pandemic to conserve resources and reduce the risk of transmission. Also, the pandemic brought attention to the importance of effective pain management in healthcare. So, there may be longer-term effects on healthcare utilization patterns, which could influence the demand for products like Bupivacaine Hydrochloride Injection.

The chronic pain management segment is expected to be the largest during the forecast period

The chronic pain management segment is estimated to have a lucrative growth. Bupivacaine Hydrochloride is often used in regional anaesthesia techniques such as epidural and nerve block procedures. It provides pain relief in specific areas of the body without causing a loss of consciousness. Compared to some other local anaesthetics, bupivacaine hydrochloride has a lower rate of systemic absorption. Its longer duration of action, preservation of muscle strength, enhanced patient comfort and satisfaction drives the segment demand.

The specialty clinics & pain management centers segment is expected to have the highest CAGR during the forecast period

The specialty clinics & pain management centers segment is anticipated to witness the highest CAGR growth during the forecast period. Bupivacaine Hydrochloride Injection is a valuable tool in the arsenal of pain management centers, offering a reliable and effective means to alleviate pain, enhance patient comfort, and support rehabilitation efforts. Bupivacaine has a longer duration of action compared to some other local anaesthetics. Due to its prolonged duration of action, bupivacaine can be especially useful in ambulatory or outpatient settings where extended pain relief is needed after a procedure.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period. The Asia-Pacific region has witnessed a rise in surgical procedures, driven by factors such as population growth, increased access to healthcare, and a rising aging population. China, India, Japan, South Korea, and Australia, have been investing significantly in their healthcare infrastructure. The adoption of advanced medical technologies and equipment has improved the quality of surgical care in the region. Further, the rising awareness of pain management and presence of strong key players are fuelling the market demand.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period. The region is well known for its technological advancements in healthcare. The aging population in North America has led to an increase in chronic pain conditions. Also, North America has a high rate of surgical procedures, including both elective and non-elective surgeries. In addition, the market for pharmaceuticals in the region is highly competitive, with both generic and brand-name manufacturers. Further, its research and development initiatives and strong market competition is boosting the North American market.

Key players in the market

Some of the key players profiled in the Bupivacaine Hydrochloride Injection Market include: Hikma Pharmaceuticals, Pfizer Inc., Fresenius Kabi AG, Baxter International Inc., AstraZeneca, AuroMedics Pharma LLC, Areva, SteriMax Inc., Shanghai Harvest Pharmaceutical Co., Southwest Pharma, Hunan Kelun Pharmaceutical, Aurobindo pharma and Sagent Pharmaceuticals.

Key Developments:

In December 2021, Hikma Pharmaceuticals PLC, the multinational pharmaceutical company, announced that it launched Bupivacaine HCl Injection, USP through its US affiliate, Hikma Pharmaceuticals USA Inc.

In July 2016, India-based pharmaceutical manufacturing company, Aurobindo pharma has got approval from the US food and drug administration (USFDA) to produce and market its anaesthetic Bupivacaine Hydrochloride injection in the American market.

Concentrations Covered:

• 0.25%
• 0.50%
• 0.75%
• Other Concentrations

Volumes Covered:

• Small Volume (5 ML)
• Medium Volume (10 ML)
• Large Volume (>20 ML)

Packagings Covered:

• Single-Dose Vials
• Multi-Dose Vials
• Ampoules

Applications Covered:

• Surgical Anaesthesia
• Obstetric Anaesthesia
• Chronic Pain Management
• Orthopedic Procedures
• Cardiovascular Procedures
• Neurological Procedures
• Dental Procedures
• Other Applications

End Users Covered:

• Ambulatory Surgical Centers (ASCs)
• Hospitals & Clinics
• Specialty Clinics & Pain Management Centers
• Dental Clinics
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Application Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Bupivacaine Hydrochloride Injection Market, By Concentration

• 5.1 Introduction
• 5.2 0.25%
• 5.3 0.50%
• 5.4 0.75%
• 5.5 Other Concentrations

6 Global Bupivacaine Hydrochloride Injection Market, By Volume

• 6.1 Introduction
• 6.2 Small Volume (5 ML)
• 6.3 Medium Volume (10 ML)
• 6.4 Large Volume (>20 ML)

7 Global Bupivacaine Hydrochloride Injection Market, By Packaging

• 7.1 Introduction
• 7.2 Single-Dose Vials
• 7.3 Multi-Dose Vials
• 7.4 Ampoules

8 Global Bupivacaine Hydrochloride Injection Market, By Application

• 8.1 Introduction
• 8.2 Surgical Anesthesia
• 8.3 Obstetric Anesthesia
• 8.4 Chronic Pain Management
• 8.5 Orthopedic Procedures
• 8.6 Cardiovascular Procedures
• 8.7 Neurological Procedures
• 8.8 Dental Procedures
• 8.9 Other Applications

9 Global Bupivacaine Hydrochloride Injection Market, By End User

• 9.1 Introduction
• 9.2 Ambulatory Surgical Centers (ASCs)
• 9.3 Hospitals & Clinics
• 9.4 Specialty Clinics & Pain Management Centers
• 9.5 Dental Clinics
• 9.6 Other End Users

10 Global Bupivacaine Hydrochloride Injection Market, By Geography

• 10.1 Introduction
• 10.2 North America
  • 10.2.1 US
  • 10.2.2 Canada
  • 10.2.3 Mexico
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 Italy
  • 10.3.4 France
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 New Zealand
  • 10.4.6 South Korea
  • 10.4.7 Rest of Asia Pacific
• 10.5 South America
  • 10.5.1 Argentina
  • 10.5.2 Brazil
  • 10.5.3 Chile
  • 10.5.4 Rest of South America
• 10.6 Middle East & Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 UAE
  • 10.6.3 Qatar
  • 10.6.4 South Africa
  • 10.6.5 Rest of Middle East & Africa

11 Key Developments

• 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 11.2 Acquisitions & Mergers
• 11.3 New Product Launch
• 11.4 Expansions
• 11.5 Other Key Strategies

12 Company Profiling

• 12.1 Hikma Pharmaceuticals
• 12.2 Pfizer Inc.
• 12.3 Fresenius Kabi AG
• 12.4 Baxter International Inc.
• 12.5 AstraZeneca
• 12.6 AuroMedics Pharma LLC
• 12.7 Areva
• 12.8 SteriMax Inc.
• 12.9 Shanghai Harvest Pharmaceutical Co.
• 12.10 Southwest Pharma
• 12.11 Hunan Kelun Pharmaceutical
• 12.12 Aurobindo pharma
• 12.13 Sagent Pharmaceuticals